1. Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas
- Author
-
Elaine S. Jaffe, Wyndham H. Wilson, Thomas A. Waldmann, Christopher Melani, Andrea Nicole Lucas, Seth M. Steinberg, Joseph Roswarski, Stefania Pittaluga, and Mark Roschewski
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,Vincristine ,medicine.medical_specialty ,Adolescent ,Cyclophosphamide ,Kaplan-Meier Estimate ,Article ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Prednisone ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Doxorubicin ,EPOCH (chemotherapy) ,Alemtuzumab ,Etoposide ,Aged ,Neoplasm Staging ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Lymphoma ,Lymphoma, Extranodal NK-T-Cell ,body regions ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,business ,psychological phenomena and processes ,030215 immunology ,medicine.drug - Abstract
To evaluate the feasibility and clinical efficacy of the combination of alemtuzumab with dose-adjusted etoposide/cyclophosphamide/doxorubicin/vincristine/prednisone (DA-EPOCH) as upfront therapy for untreated aggressive T and NK cell lymphomas, a phase 1/2 trial was conducted. Thirty patients were treated with the study regimen, consisting of alemtuzumab on day 1 of a 21 day cycle with standard dosing of DA-EPOCH for 6-8 cycles. Alemtuzumab 30 mg IV was used for the phase 2 component. Of 30 treated patients, 17 had a complete response (CR) and eight had a partial response (83.3% overall response rate). The median overall survival and progression-free survival were 20.2 and 6.6 months, respectively. There were five treatment-related deaths on study mainly due to infectious complications, including one case each of disseminated toxoplasmosis and pneumonia and two cases of sepsis. Alemtuzumab with DA-EPOCH is of limited clinical utility due to unacceptable toxicity, despite the high rate of CR.
- Published
- 2019
- Full Text
- View/download PDF